Trice Medical

Jeffrey O'Donnell is a serial entrepreneur with extensive experience in the medical device industry, having founded and led several companies to successful exits, including Embrella Cardiovascular and PhotoMedex. This background in leading emerging medical technology firms has been instrumental in shaping Trice Medical's trajectory. The current President and CEO, Mark Foster, joined in 2016 after holding leadership roles at Smith & Nephew and Boston Scientific, bringing over two decades of experience in the medical device field. His leadership has guided the company's evolution from a purely diagnostic focus to a broader therapeutic platform.

The company’s core technology is a portable, tablet-based imaging platform that combines handheld arthroscopy and ultrasound capabilities. Its flagship product family, the mi-eye, is a single-use, disposable needlescope that provides direct visualization inside a joint. The mi-eye 3, for instance, is an FDA-cleared needlescope with an integrated camera and light source that pairs with the mi-tablet, offering high-resolution imaging in a handheld device. This allows for immediate diagnosis during an initial office visit. Complementing the mi-eye is the mi-ultra, a handheld ultrasound transducer optimized for musculoskeletal applications, enabling a comprehensive evaluation of the joint and surrounding soft tissue, as well as guiding injections. Through strategic acquisitions, such as Seg-WAY Orthopedics in 2019 and Tenex Health in 2021, Trice Medical has expanded its portfolio to include minimally invasive therapeutic solutions. These include the Seg-WAY system for endoscopic carpal tunnel release and the Tenex Health TX technology, which uses ultrasonic energy to treat chronic tendon pain.